Investor Center
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing a new generation of multi-mechanism drugs for the treatment of cancer and inflammatory diseases. EntreMed’s drug candidates target disease cells and the blood vessels that nourish them. The company’s goal is to develop and commercialize therapeutic products based on its scientific expertise in angiogenesis, cell signaling, cell cycle regulation and inflammation—processes that are vital to the progression of cancer and other diseases.
August 6, 2009
 |
2008 10-K Download the 2008 10-K (PDF, 680 KB) Download the Annual Meeting Notice and Proxy Statement (PDF, 450 KB) |
Upcoming Events
There are no upcoming events at this time.
Webcasts and Presentations
Business Presentation - December 2, 2008 1:35pm ET
November 25, 2008
EntreMed to Present at the New York Society of Security Analysts Industry Conference
View the presentation
November 25, 2008
EntreMed to Present at the New York Society of Security Analysts Industry Conference
View the presentation
EntreMed In the News
Oncology Business Review
May 19, 2008
On-Conversation with EntreMed, Inc. President & CEO, James S. Burns, and Senior Vice President, R&D, Kenneth Bair
Read the article
May 19, 2008
On-Conversation with EntreMed, Inc. President & CEO, James S. Burns, and Senior Vice President, R&D, Kenneth Bair
Read the article
Drug Discovery and Development
July 1, 2007
Drug Discovery and Development - EntreMed’s Roller Coaster Ride
Read the article
July 1, 2007
Drug Discovery and Development - EntreMed’s Roller Coaster Ride
Read the article
10-K Downloads
2004, 2005, 2006, 2007, 2008
SEC Filings
View all SEC filings, View only Section 16 SEC filings
Please note that the above are links to www.sec.gov, a third-party web site. EntreMed, Inc. does not maintain nor provide any information directly to www.sec.gov, and therefore makes no representations or warranties regarding the the information contained therein. Further, EntreMed takes no responsibility for supplementing, updating, or correcting any information found on www.sec.gov.
Corporate Governance Documents
Code of Ethics, Audit Committee Charter, Compensation Committee Charter, Nominating and Corporate Governance Committee Charter
Safe Harbor Information
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results may differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under "Risk Factors," including risks relating to our ability to obtain additional financing; the early-stage products under development; uncertainties relating to clinical trials; our success in the further clinical development of Panzem®; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
